Importance of Human Leukocyte Antigen (HLA) Class I and II Alleles on the Risk of Multiple Sclerosis by Link, Jenny et al.
Importance of Human Leukocyte Antigen (HLA) Class I
and II Alleles on the Risk of Multiple Sclerosis
Jenny Link
1*, Ingrid Kockum
1,A ˚slaug R. Lorentzen
2,3, Benedicte A. Lie
2,4, Elisabeth G. Celius
3,
Helga Westerlind
1, Marie Schaffer
5, Lars Alfredsson
6, Tomas Olsson
1, Boel Brynedal
1, Hanne F. Harbo
3,7,
Jan Hillert
1
1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 2Institute of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway,
3Department of Neurology, Oslo University Hospital, Ulleva ˚l, Oslo, Norway, 4Department of Medical Genetics, University of Oslo, Oslo, Norway, 5Department of
Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, 6Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 7Institute of Clinical
Medicine, University of Oslo, Oslo, Norway
Abstract
Multiple sclerosis (MS) is a complex disease of the central nervous system of unknown etiology. The human leukocyte
antigen (HLA) locus on chromosome 6 confers a considerable part of the susceptibility to MS, and the most important factor
is the class II allele HLA-DRB1*15:01. In addition, we and others have previously established a protective effect of HLA-A*02.
Here, we genotyped 1,784 patients and 1,660 healthy controls from Scandinavia for the HLA-A, HLA-B, HLA-C and HLA-DRB1
genes and investigated their effects on MS risk by logistic regression. Several allele groups were found to exert effects
independently of DRB1*15 and A*02, in particular DRB1*01 (OR=0.82, p=0.034) and B*12 (including B*44/45, OR=0.76,
p=0.0028), confirming previous reports. Furthermore, we observed interaction between allele groups: DRB1*15 and
DRB1*01 (multiplicative: OR=0.54, p=0.0041; additive: AP=0.47, p=4610
206), DRB1*15 and C*12 (multiplicative: OR=0.37,
p=0.00035; additive: AP=0.58, p=2.6610
205), indicating that the effect size of these allele groups varies when taking
DRB1*15 into account. Analysis of inferred haplotypes showed that almost all DRB1*15 bearing haplotypes were risk
haplotypes, and that all A*02 bearing haplotypes were protective as long as they did not carry DRB1*15. In contrast, we
found one class I haplotype, carrying A*02-C*05-B*12, which abolished the risk of DRB1*15. In conclusion, these results
confirms a complex role of HLA class I and II genes that goes beyond DRB1*15 and A*02, in particular by including all three
classical HLA class I genes as well as functional interactions between DRB1*15 and several alleles of DRB1 and class I genes.
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Introduction
In the past few years, the number of genes known to influence
the risk of multiple sclerosis (MS, OMIM:126200), a chronic
inflammatory disease of the central nervous system, has increased
dramatically. Even so, the by far most strongly acting genetic
signal originates from the human leukocyte antigen (HLA) gene
complex on the short arm of chromosome 6. The discovery of the
class II risk haplotype, later shown to be best represented by the
HLA-DRB1*15:01 allele, was made almost 40 years ago and was
only recently shown to be accompanied by an independent
protective allele group in class I, HLA-A*02 [1,2,3,4,5,6]. In
addition to these two established alleles a series of reports have
suggested additional MS risk alleles as well as interactions between
alleles [7]. Within the HLA-DRB1 gene, the allele groups
DRB1*03, DRB1*14, DRB1*07 and DRB1*11 have all been
suggested to influence risk in MS [8,9,10,11]. Furthermore,
interactions have been implicated among DRB1 allele groups:
DRB1*08, DRB1*10 and DRB1*01 were reported to interact with
DRB1*15 in modifying susceptibility to MS [8,10].
An increasing number of studies has recently confirmed the
importance of genes in the class I region on MS susceptibility
[12,13]. The HLA-A*02 association was first identified in a limited
Swedish cohort [2] and was later confirmed in a larger
Scandinavian cohort [1]. In addition, studies including not only
HLA-DRB1 and HLA-A, but also HLA-B and/or HLA-C have
indicated additionally associated alleles [14,15,16,17], including
HLA-C*08, HLA-C*05 and HLA-B*44. A single nucleotide
polymorphism (SNP) genotyping approach, where HLA alleles
were imputed based on linkage disequilibrium with SNP markers,
found a signal of association from HLA-B*44:02 when condition-
ing on DRB1*15 [18]. HLA-B*44 was also found associated
independently from DRB1*15 in a meta-analysis of available SNP
genome scans [19]. The MOG gene, encoding the myelin
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has been repeatedly studied [20,21] but its signal of association
seems most likely secondary to HLA-A*02 [15].
Several studies have tried to distinguish which of the class I
alleles or genes that are responsible for the class I region signal.
When carried together, HLA-C*05 was reported to enhance the
protective effect of HLA-A*02 [15], but this could not be replicated
in the Scandinavian population [17]. HLA-C*05 has been seen to
be secondary to both HLA-A*02 and HLA-B*44 whereas B*44 was
not secondary to HLA-A*02 [22]. In addition to this, a SNP screen
revealed a SNP associated to MS in the untranslated region of
HLA-G that could not be ruled out to be independent from either
HLA-A,- B or -C alleles [23].
In this study, we aimed at assessing signals from the three
classical class I genes together with HLA-DRB1 in a large cohort
consisting of Swedish and Norwegian MS patients and controls.
All three major genes in class I as well as HLA-DRB1 have been
genotyped with robust direct HLA genotyping techniques and the
association with MS and potential interactions were assessed with
logistic regression.
Results
The aim of this study was to investigate the association to MS of
all three classical HLA class I genes, HLA-A, HLA-B, HLA-C as
well as the HLA class II gene, HLA-DRB1, in a Scandinavian
cohort of 1,784 patients and 1,660 controls. The nature of the
previously reported effects within class I in MS was also evaluated.
HLA class I and II allele groups in MS risk
We started by assessing the mode of inheritance of the two
already established genetic factors within the HLA region to
determine how to proceed with the analysis. HLA-DRB1*15 was
seen to behave multiplicatively as the odds ratio for carrying one
copy of DRB1*15 (95% confidence interval) was 3.03 (2.62–3.52)
and 11.47 (7.74–16.99) for carrying two copies. In contrast HLA-
A*02 behaved dominantly, the odds ratio for carrying one copy of
A*02 was 0.70 (0.61–0.81) and 0.57 (0.45–0.71) for carrying two
copies. Therefore these particular allele groups were encoded
accordingly throughout this study (see material and methods
section for details).
There was no difference between coding the additional allele
groups as gene dose (0, 1 or2) or carriage (0 or 1) when assessing
which allele groups should be in the final regression model (data
not shown), but the overall fit of the model (deviance) was superior
in the dominant model. Therefore only carriage coded results will
be presented. In the final model DRB1*15 and B*14 were
positively associated with MS while A*02, B*12, DRB1*01 and
DRB1*07 were negatively associated (Table 1). Thus, HLA-B
seemed to influence MS risk in addition to HLA-A and HLA-DRB1
but HLA-C was not independently associated with MS at this stage.
Next, we wanted to assess whether groups stratified by
DRB1*15 carriage display different genetic etiology. 1,051 cases
and 476 controls were DRB1*15 positive while 733 cases and
1,184 controls were negative for DRB1*15 in this cohort. Allele
group frequencies are shown in Table S1. Six allele groups
reached significance in the HLA-DRB1*15 negative group whereas
four allele groups reached significance in the DRB1*15 positive
group (Table 2). Surprisingly, apart from A*02, which was
negatively associated in both strata, the other allele groups were
different between the groups. In the negative group we found
associations to B*14, A*02, DRB1*07, B*12, A*10 and B*18 and
in the positive group both DRB1*15 and A*02 as well as C*12 and
DRB1*01 were associated (Table 2). An importance of DRB1*01
in DRB1*15 positives has previously been reported [8] and was
thus confirmed. In addition, even allele groups of HLA-C may
influence the risk of MS, at least in the DRB1*15 positive
individuals.
The difference in association pattern between the DRB1*15
positive and negative subpopulation prompted us to formally assess
the presence of interaction. The allele groups DRB1*07, B*12,
B*18, A*10 and B*14, failed to show a significant interaction with
DRB1*15. However two allele groups (C*12 and DRB1*01) did
reach significant statistical interaction when using either departure
from multiplicativity as definition, or when analyzed by attributable
proportion due to interaction (AP) (i.e. departure from additivity)
(Table 3). In addition, A*02 showed statistically significant
interaction with DRB1*15 in AP analysis only.
In conclusion, we observed significant support for interaction
for MS risk between HLA class I and class II genes as well as
between allele groups of HLA-DRB1 itself. This confirms and
extends previous reports of such interactions [8].
Evaluation of protective effects of class I allele groups in MS
Previous reports have indicated HLA-C*05 and HLA-B*44 as
important allele groups in MS, and Healy et al used logistic
regression to study these allele groups with the previously
established HLA-DRB1*15 and HLA-A*02 as covariates [22]. It
has also been reported that the protective effect of A*02 is
enhanced when also carrying C*05 in the Italian population [14].
In a previous study, we failed to confirm this role of C*05 [17].
Now, when being able to study also B*12, the protective effect of
HLA-C*05 was seen to be secondary to both B*12 and HLA-A*02
due to linkage disequilibrium (Table S2). Again, we failed to
confirm an augmented protective effect of A*02 when carrying
C*05 (A*02 alone OR=0.66, p=5.95610
209; carrying A*02 and
C*05 OR=0.64, p=2.65610
204).
Table 1. Risks carried by each of the nominally significant allele groups from the final logistic regression analyses.
Allele group p-value (nominal) p-value (FDR) OR (95% C.I.) Frequency Cases (%) Frequency Controls (%)
DRB1*15 (dose) 2.51610
263 2.26610
262 3.03 (2.67–3.46) 35.4 15.3
A*02 5.42610
208 2.44610
207 0.67 (0.58–0.77) 27.7 34.6
B*14 6.96610
205 0.00013 2.05 (1.45–2.94) 2.7 1.8
DRB1*07 0.0016 0.0020 0.70 (0.56–0.87) 5.0 8.5
B*12 0.0025 0.0028 0.76 (0.63–0.91) 8.8 13.1
DRB1*01 0.034 0.034 0.82 (0.68–0.98) 7.7 11.9
FDR=False discovery rate, performed in R, based on the paper [37].
doi:10.1371/journal.pone.0036779.t001
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attempts to map genetic effects within the HLA gene region. Early
attempts failed to find much residual effects after stratifying for
DRB1*15 [13]. More recently, Cree et al reported an association
to the SNP rs4959039 (A/G), located in the downstream
untranslated region of HLA-G [23]. This SNP was found to be
associated independently of a DRB1*15 tagging SNP but it could
not be determined if it tagged HLA-A*02 or was independent of
this allele group. We genotyped this marker in 1,978 patients and
1,782 controls previously genotyped for HLA-A and HLA-DRB1
and observed a minor allele frequency (G) of 0.26 in cases and 0.33
in controls. A haplotype analysis was performed using UN-
PHASED to elucidate the correlation between rs4959039 and
HLA-A. The correlation between minor allele rs4959039
G and
HLA-A*02 was clearly higher compared to the other top five HLA-
A allele groups with a D9 of 0.90 and r
2 of 0.78. There was no
residual association with the SNP when correcting for A*02
(p=0.90) in logistic regression, convincingly showing that the
rs4959039 effect was secondary to A*02.
Haplotype analysis
Allele group association analysis assesses the combined risk of all
the haplotypes carrying certain allele groups. The effects of
associated HLA allele groups in logistic regression are independent
of each other but a shown risk or protection can, alternatively,
indicate a stronger effect at the haplotype level. The property of
the HLA gene complex to harbor these extended conserved
haplotypes often spanning several megabases, may be seen as an
argument against case-control design where phase cannot be
deduced. To compensate for this void, we attempted to infer
haplotypes using UNPHASED 3.0.13, hypothesizing that the
greater available numbers in this case control study compared with
available family cohorts could outweigh the disadvantages. Table 4
contains the 20 most frequent inferred haplotypes from this
analysis. Only haplotypes with a probability of at least 80% were
used in the association analysis. Similar results were obtained
when all haplotypes, irrespectively of probability, were included
(data not shown).
The haplotype analysis revealed several nominally significant
associated haplotypes in spite of low frequencies. Interestingly,
almost all of the most common haplotypes contain one or more
allele groups found to be associated in the final full logistic
regression model (Table 1). A striking finding was that almost all
DRB1*15 carrying haplotypes in Table 4 were risk haplotypes and
all A*02 carrying haplotypes were protective as long as they did
not carry DRB1*15. There was however an interesting exception
(haplotype number 12 in Table 4) where A*02 together with C*05
and B*12 abolished the risk of DRB1*15. To further investigate
these allele groups, logistic regressions with the 20 most common
haplotypes carrying each of these allele groups was created (Table
S3, S4, S5, S6). Indeed almost all DRB1*15 haplotypes were risk
haplotypes even though not all reached significance for association
with MS (Table S3). The exception was again the haplotype
carrying A*02, C*05 and B*12, OR (95% C.I.)=1.13 (0.62–2.07)
and p-value=0.71 thus somewhat lowering the risk of DRB1*15.
The same analysis was done for A*02 bearing haplotypes (Table
S4), and also here the pattern from Table 4 was repeated. Most of
the B*12 haplotypes were protective unless carrying DRB1*15 or
DRB1*06 (Table S5). When looking at the C*05 bearing
haplotypes, C*05 was only seen in haplotypes with either B*12,
B*18 or B*05 and varied in risk for MS (Table S6). One should
bear in mind that these haplotypes were indeed estimated and the
haplotype frequencies were small.
The protective haplotype carrying A*02, C*05 and B*12
(hereafter referred to as ‘‘protective class I haplotype’’ or
abbreviated as ‘‘H’’) was further studied for the nature of its
protective properties in relation to DRB1*15 and if any of its alleles
were sole responsible for the protective effect. The protective class I
haplotype was independent of DRB1*15 and was protective on both
DRB1*15 positive and DRB1*15 negative haplotypes (Table 5).
Chromosomes positive for both A*02 and B*12 but lacking
C*05 was the only combination of the protective class I haplotype
that did not have a significantly higher risk than chromosomes
carrying all three allele groups (H+)(Figure 1). Thereby indicating
that a haplotype containing at least A*02 and B*12 seems
responsible for this protective effect in our cohort.
Table 2. Risk carried by each of the nominally significant allele groups in the logistic regression model for carriage coded DRB1*15
negative and positive strata.
DRB1*15 negative
Allele group p-value (nominal) p-value (FDR) OR (95% C.I.) Frequency Cases (%) Frequency Controls (%)
B*14 0.00040 0.0018 2.08 (1.39–3.13) 4.0 2.2
A*02 0.00086 0.0026 0.72 (0.59–0.87) 27.8 34.7
DRB1*07 0.0032 0.0058 0.66 (0.5–0.87) 6.8 9.9
B*12 0.0045 0.0068 0.71 (0.56–0.9) 9.3 14.2
A*10 0.012 0.012 1.52 (1.09–2.1) 6.3 3.7
B*18 0.011 0.012 1.69 (1.13–2.54) 4.0 2.2
DRB1*15 positive
Allele group p-value (nominal) p-value (FDR) OR (95% C.I.) Frequency Cases (%) Frequency Controls (%)
DRB1*15 7.99610
211 5.60610
211 3.87 (2.61–5.92) 60.1 53.2
A*02 3.31610-05 0.00012 0.62 (0.49–0.78) 27.6 34.2
C*12 0.00021 0.00050 0.5 (0.35–0.72) 4.1 6.6
DRB1*01 0.0052 0.0052 0.59 (0.41–0.86) 3.6 6.3
Country of origin and gender were included in the models as covariates. DRB1*15 was coded as dose (0,1,2), all other allele groups were coded for carriage (0,1).
doi:10.1371/journal.pone.0036779.t002
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the context of DRB1*15, it was seen that compared to doubly
negative chromosomes (‘‘H2 DRB1*15-’’ neither carrying the
protective class I haplotype nor DRB1*15), chromosomes carrying
DRB1*15 but negative for protective class I haplotype had an OR
of 3 (p-value 1.08610
263) (Figure 2). Chromosomes carrying the
protective class I haplotype but not DRB1*15 had a negative
association compared to doubly negative chromosomes (OR 0.42,
p-value 3.42610
206). Chromosomes carrying both A*02, C*05,
B*12 and DRB1*15 did not differ in risk from doubly negatives
(OR 1.25, p-value 1). Thus, this haplotype diminishes the risk of
DRB1*15 also in this analysis.
Analysis of the haplotype was also performed with logistic
regression to be able to account for carriage of A*02, C*05 and
B*12 as well as baseline covariates as country of origin, gender and
carriage of DRB1*15. After including the three class I allele groups
and adding carriage of the haplotype into the model both A*02
(OR 0.73 p=0.00015), B*12 (OR 0.69 p=0.0032) and the
protective haplotype (OR 0.54 p=0.0080) were significantly
associated to MS. Carriage of C*05 was not significant and
DRB1*15 was independently associated to MS in the model (OR
3.28 p=,2610
216). The overall fit (deviance) of the model was
significantly better than the model with only baseline variables and
carriage of the three class I allele groups (p=0.0076).
Discussion
The aim of this study was to investigate the class I and class II
allele groups and their effect on MS susceptibility in the
Scandinavian population. All 3,444 individuals were genotyped
for HLA-A, -B, -C, and -DRB1.
We have confirmed and extended previous reports of a complex
genetic influence of the HLA region on MS susceptibility. The two
strongest effects are clearly conferred by DRB1*15 and A*02 but
we could also show that additional DRB1 allele groups contribute
to risk as well as allele groups of HLA-B which seem more
important than those of HLA-C. Further, several alleles were
interacting with DRB1*15, exerting their effects either in DRB1*15
positive or negative individuals. However, it was clear that no
other class I allele group equaled the effect of A*02.
A novelty of this study is the application of formal interaction
analysis. We could see that several of the associations from the full
analysis persisted in only one of the two DRB1*15 strata. Two HLA
allele groups did interact with DRB1*15,n a m e l yC*12 and
DRB1*01. A protective effect of DRB1*01 was seen both in the full
sample set and in the DRB1*15 positives. This trans interaction has
been discussed previously where an under transmission of DRB1*01
was detected in DRB1*15 positive affected children in family trios
[8]. How such an interaction could be explained molecularly is
potentially important as it may give clues on how HLA genotype
exerts its role on MS risk. Explanations could potentially involve
competition for peptides or trans-coded HLA class II heterodimers
[24]. The latter mechanism would be more likely to occur at the
HLA-DQ locus where both a-a n db-chains are polymorphic (in
contrast to the almost non-polymorphic DRa-chain).
The interaction between DRB1*15 and A*02 and DRB1*15 and
C*12 suggests that they are involved in the same pathway of
developing disease but not necessarily exerting their effect at the
same time or interact physically since they act mainly in different
immune pathways. This data supports the hypothesis that viral
infections play an important role in susceptibility to MS.
Traditionally, it has been argued that the existence of extended
haplotypes spanning HLA class I and class II indicates a functional
property being evolutionarily advantageous and potentially
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36779important for the risk of autoimmune disease. As shown in Table 4,
all haplotypes were of limited frequency and none of the most
common ones showed stronger risk than the most clearly
associated allele groups. Haplotypes carrying DRB1*15 were
almost always risk haplotypes regardless of which other allele
groups that were present, indicating that it is probably the
DRB1*15 allele itself that confers the risk of MS. The protective
class I haplotype suggests a protection against MS that must be
further studied to evaluate two things: 1) is this haplotype tagging
some other marker in the HLA or 2) is the protection inflated by
combining several independent protective markers that when
carried together overcome the effect of DRB1*15.
Table 5. Independence of the protective class I haplotype from DRB1*15 demonstrated in two ways.
Haplotype + Haplotype -
Cases Controls Cases Controls OR (95% CI) p-value
DRB1*15 + 24 23 1027 409 0.42 (0.23–0.74)* 0.0041
DRB1*15 2 43 122 1880 2244 0.42 (0.30–0.60)* 1.141610
206
OR (95% CI) 2.96 (1.52–5.78)** 3.00 (2.63–3.41)**
p-value 0.0021 ,2.2610
216
Counts are made in number of chromosomes carrying the haplotypes estimated in UNPHASED within the cohort. ‘‘Haplotype +’’ was all chromosomes with both A*02,
C*05 and B*12 disregarding the DRB1 locus, ‘‘Haplotype –’’were all chromosomes that did not have all three allele groups (A*02, C*05 and B*12) at once, still disregarding
DRB1. ‘‘DRB1*15+’’ was all chromosomes carrying DRB1*15 disregarding class I allele groups and vice versa for the ‘‘DRB1*15 –’’.
*) Odds ratio for the class I haplotype within DRB1*15 positive and negative haplotypes respectively.
**) Odds ratio for DRB1*15 within the class I haplotype and class I haplotype negative respectively. Note: Class I haplotype negative chromosomes can carry parts of the
protective haplotype (i.e. A*02 but in that case not C*05 and/or B*12).
doi:10.1371/journal.pone.0036779.t005
Figure 1. Odds ratios for haplotypes carrying any combination of A*02, C*05 and B*12. Odds ratios for haplotypes containing one or two of
the allele groups of the protective class I haplotype compared to the full protective class I haplotype disregarding the DRB1 locus. Chromosomes
carrying both A*02 and B*12 was the only combination within this setting that had the same risk as the protective haplotype, the risk of MS was
significantly higher for all other combinations.‘‘+’’=Chromosomes carrying the allele group specified to the left, ‘‘H2’’=chromosomes carrying other
allele group than the one specified to the left (i.e. not the complete protective haplotype). OR=odds ratio with 95% confidence interval, nominal p-
value and Bonferroni corrected p-values derived from chi square test with full protective haplotype as reference.
doi:10.1371/journal.pone.0036779.g001
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36779Recently, the International MS Genetics Consortium (IMSGC)
published an analysis of SNP-derived inferred HLA genotypes as
part of a genome wide association study on close to 10.000 patients
[25]. Also here, a dominance of a DRB1*15 effect was followed by
an influence of A*02. In addition, residual effects were explained
by other DRB1 alleles and little further signal in class I was
detected which would be in line with our suggestion of the
protective class I haplotype. Besides from harboring the classic
HLA genes, the HLA gene complex is rich in other genes of
importance for immune function. It is plausible that such genes are
of importance also in MS but the proximity of the two most
strongly acting MS genes is likely to obscure such signals making
them difficult to identify. In essence the main result of the IMSGC
screen of the HLA gene complex is that the strongest effects indeed
map to the classic HLA genes themselves, both for the class II and
class I subregions.
The confirmation of an importance for one or even several
HLA class I genes in MS, paralleled by findings in other
autoimmune diseases [18], points toward a possible importance
of class I restricted CD8+ T-cells. Our group has previously
studied this in the MS-like model experimental autoimmune
encephalomyelitis (EAE) after immunization with myelin basic
protein (MBP). Here, protection against disease was found in rats
carrying the MHC class I u and MHC class II a haplotype, an
effect efficiently abrogated by antibodies against CD8+ cells [26].
A series of studies using double and triple transgenic mice has
further illustrated how class I restricted lymphocytes may
contribute to MS-like autoimmune events [27,28]. The explana-
tion could be that a combination of class I allele groups, such as
A*02-C*05-B*44, immunologically counteract the negative effect
of carrying DRB1*15 in class II when encountering some pathogen
involved in MS susceptibility. This mechanism could vary in effect
size between populations since the environmental challenge may
be different in different areas.
In conclusion, evidence is suggesting that HLA class I and class
II effects contribute and interact in determining the risk of MS, as
in autoimmune diseases in general. These genes are the most
strongly associated with MS and the functional background to
these effects should be given increased attention.
Materials and Methods
Subjects
All 1784 patients were diagnosed with MS according to the
McDonald or Poser criteria [29,30]. The 1,229 Swedish patients
were gathered through the neurology clinics at Karolinska
University Hospital, Stockholm, Sweden. The ethical board of
Karolinska Institutet approved of the study and oral or written
informed consent wasobtainedfromall participants according tothe
ethical permission. From Norway 555 MS patients were collected
from the Oslo MS registry at the Department of Neurology, Ulleva ˚l,
Oslo University Hospital. The study was approved by the Regional
Committee for Medical and Health Research Ethics, and written
informed consent was obtained from all individuals.
Figure 2. Odds ratios for chromosomes carrying only the protective haplotype or DRB1*15 or both. Chromosomes carrying both
DRB1*15 and the protective class I haplotype do not differ in risk of MS from chromosomes not carrying either of them (reference). DRB1*15 carriage
increase risk of MS significantly and carriage of the class I haplotype significantly decrease risk of MS. Counts are measured in chromosomes and only
individuals with estimated haplotypes with a probability of more than 80% were included. ‘‘+’’=Chromosomes positive for the protective haplotype
or DRB1*15,‘ ‘ 2’’ and ‘‘H2’’=chromosomes negative for DRB1*15 or the protective haplotype. OR=odds ratio with 95% confidence interval, nominal
p-value and Bonferroni corrected p-values derived from chi square test with doubly negative chromosomes as reference.
doi:10.1371/journal.pone.0036779.g002
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36779Of the 1,660 healthy controls used in this study, 1,062 were
Swedish blood donors of Nordic origin giving informed consent.
From Norway 598 healthy controls were recruited from the
Norwegian Bone Marrow Donor Registry, (http://www.
nordonor.org/). Age and gender distribution for cases and controls
are shown in Table 6.
Methods
HLA genotyping was performed using several techniques. The
Swedish cohort was genotyped for HLA-DRB1, HLA-A and HLA-C
using Olerup SSP
TM HLA Low resolution Kit [31] and for HLA-B
using a Luminex based reverse PCR-SSO (LABTypeH SSO from
One Lambda, Inc., Canoga Park, CA, USA). The Norwegian
patients were genotyped using PCR with sequencing-based
approach [32] and the controls were genotyped with various
techniques used in the Norwegian Bone Marrow Donor registry
laboratory, (http://www.nordonor.org/).
SNP genotyping and analysis
Swedish MS cases (N=2,576) and controls (N=2,031) were
genotyped in the study for correlation analysis between a SNP
(rs4959039) in the HLA region and HLA-A*02 status. This group
of individuals consisted of the above described patients and
controls plus newly diagnosed patients and matched controls from
the EIMS study described elsewhere [33]. SNP genotyping was
performed using the TaqManH SNP Genotyping Assays (Applied
Biosystems, USA) according to the manufacturer’s manual. HLA-A
and HLA-DRB1 genotyping was formerly performed using Olerup
SSP
TM HLA Low resolution Kit [31]. In total, 1,978 patients and
1,782 controls had full information on gender, the SNP, HLA-A
and HLA-DRB1 genotypes and were used in the correlation
analysis.
Serological allele groups
As some Norwegian controls were not genotyped down to two
digit level, major allele groups were created where there was an
information shortage. The allele grouping is shown in Table 7. It
should be noted that the B*44 allele group which has previously
been reported to be associated to MS is included in the B*12
major allele group together with B*12 and B*45. However, B*44 is
the dominating allele within this group (90%).
Statistical methods
The software used for statistical calculations in this paper was R
version 2.6.2 [34] and UNPHASED 3.0.13 [35]. Nested logistic
regression models were compared using analysis of deviance and
chi square test in R. In the logistic regressions all allele groups were
coded 0, 1, 2 (dose) or 0, 1 (carrier) depending on question and
those allele groups with a total count of less than 150
chromosomes (2.2% allele frequency) in the full cohort were
grouped within each gene into a group called X (see Table 7). This
cutoff was set to decrease complexity of the cohort and increase
power. DRB1*08, A*11, B*35 and C*02 were used as intercepts for
the full analysis as these were the most evenly distributed between
cases and controls and had a frequency of at least 5% in both
groups. First, a baseline model including the already known risk
allele groups for MS was created. This model included country of
origin, gender, HLA-DRB1*15 and HLA-A*02. Allele groups
within each gene were added to this baseline model to determine
if any allele group had an additional independent effect. Within
each model only those allele groups with a statistically significant
odds ratio were kept in the next step in which a new model was
created containing the baseline plus the significant allele groups
from all genes. Allele groups were removed using stepwise
regression until only significant ones were left. The model with
the least number of included allele groups was compared to
baseline. This analysis was performed twice with all allele groups
coded as dose (0, 1, 2) or as carriage (0, 1) (in previous literature
commonly referred to as ‘‘phenotype’’ referring to the co-
dominant expression of HLA genes), with the exceptions being
DRB1*15 which was previously seen to act multiplicatively and
was therefore always coded as dose and A*02 which had a
dominant effect in our cohort, hence always coded for carriage as
described above. When stratifying the cohort into DRB1*15
positive or negative strata, all allele groups with a total count of less
than 75 (2.5%) or 100 (2.6%) chromosomes, respectively, were
grouped as an X allele within each gene (see Table S1). When
stratifying for DRB1*15 status, A*19, B*15, C*03 and DRB1*04
were used as intercepts in the positive group and A*01, B*07, C*04
and DRB1*04 were used as intercept in the DRB1*15 negative
group . DRB1*15 was coded as dose (i.e. 2, 1 or 0 alleles) in the
DRB1*15 positive group, all other alleles were coded as carriage
(i.e. 1 or 0). The significant allele groups did not change in either
stratum when using the same intercept as in the full analysis (data
not shown).
Allele group associations were also analyzed for interaction
using deviation from multiplicativity of effects (i.e. significant
interaction term in the logistic regression model) as well as using
deviation from additivity of effects (estimated by attributable
proportion (AP) due to interaction) as criteria for interaction
[36,37]. The deviation from multiplicativity of effects analysis was
performed with 5 variables: country of origin, gender, DRB1*15
allele group carriage status, allele group carriage status and an
interaction term between DRB1*15 and the allele group investi-
gated. The individuals were coded as carriers or non carriers of the
particular risk allele group as well as for DRB1*15. In the AP
analyses, risk was defined as ‘‘not carrying the protective allele
group’’ for those allele groups whose nominal effects were
protective.
Haplotypes for individuals were estimated using UNPHASED
3.0.13 since this version of the program could handle larger
number of alleles and the tolerance for convergence was set to
10
26 due to complexity of the matrix, only printing most likely
haplotypes to file. Only individuals with a probability over 80% of
carrying the assigned haplotypes were used in the subsequent
analyses leaving2,886 individuals of 3,444 in the analysis and
excluding 48 haplotypes out of 1,279.
There was no difference in allele group distribution in different
age groups or between males and females (data not shown).
Gender was included as a covariate anyway since gender is a risk
factor for MS in itself. Country of origin was included as a
Table 6. Description of basic data concerning the subjects
studied.
Swedish Norwegian
Patients Controls Patients Controls
Number of subjects 1229 1062 555 598
Average age
(year range)
55.1 (25–89) 49.3 (24–79) 57.0 (25–93) 45.1 (29–60)
Female:Male ratio 2.5 1.7 2.8 1.9
% DRB1*15 carriers 58.5 29.5 59.8 27.3
% A*02 carriers 46.5 57.3 46.3 54.3
doi:10.1371/journal.pone.0036779.t006
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Allele group frequencies (%)
Major Allele group Patients Controls Included allele groups (% of total){
total count less than
150 chromosomes
A*01 14.9 14.3 A*01 (100) no
A*02 27.7 34.6 A*02 (100) no
A*03 20.2 16.7 A*03 (100) no
A*09 11.1 10.0 A*09 (1.9), A*23 (10.9), A*24 (87.2) no
A*10 6.1 4.3 A*10 (2.8), A*25 (44.8), A*26 (50.6), A*34 (0.3), A*66 (1.7) no
A*11 5.6 5.4 A*11 (100) no
A*19 10.3 10.0 A*19 (1.6), A*29 (14.4), A*30 (10.0), A*31 (35.2), A*32 (34.2),
A*33 (4.3), A*74 (0.3)
no
A*28 4.1 4.7 A*28 (5.3), A*68 (93.7), A*69 (1.0) no
C*01 3.6 4.5 C*01 (100) no
C*02 5.6 5.9 C*02 (100) no
C*03 17.3 21.0 C*03 (100) no
C*04 8.1 9.4 C*04 (100) no
C*05 6.6 8.5 C*05 (100) no
C*06 6.4 6.9 C*06 (100) no
C*07 39.6 32.9 C*07 (100) no
C*08 2.5 2.2 C*08 (100) no
C*12 3.8 3.3 C*12 (100) no
C*14 1.1 1.0 C*14 (100) yes
C*15 3.1 2.2 C*15 (100) no
C*16 1.5 1.9 C*16 (100) yes
C*17 0.7 0.5 C*17 (100) yes
C*18 0.0 0.0 C*18 (100) yes
B*05 5.4 4.9 B*05 (3.7), B*51 (90.4), B*52 (5.9) no
B*07 24.3 15.7 B*07 (100) no
B*08 10.6 12.0 B*08 (100) no
B*12 8.8 13.1 B*12 (7.1), B*44 (89.5), B*45 (3.5) no
B*13 0.8 1.6 B*13 (100) yes
B*14 2.7 1.8 B*14 (98.1), B*64 (0.6), B*65 (1.3) no
B*15 11.1 11.7 B*15 (83.2), B*62 (16.8) no
B*16 2.2 2.1 B*16 (6.1), B*38 (26.5), B*39 (67.3) yes
B*17 2.1 3.2 B*17 (18.2), B*57 (68.5), B*58 (13.3) no
B*18 5.6 3.3 B*18 (100) no
B*21 1.1 1.3 B*21 (2.4), B*49 (59.8), B*50 (37.8) yes
B*22 1.4 1.6 B*22 (5.0), B*55 (44.6), B*56 (50.5) yes
B*27 5.7 7.2 B*27 (100) no
B*35 7.0 7.8 B*35 (100) no
B*37 2.5 1.5 B*37 (100) yes
B*40 7.5 10.3 B*40 (80.0), B*60 (18.3), B*61 (1.8) no
B*41 0.7 0.4 B*41 (100) yes
B*42 0.0 0.0 B*42 (100) yes
B*47 0.3 0.4 B*47 (100) yes
B*48 0.1 0.2 B*48 (100) yes
B*53 0.0 0.0 B*53 (100) yes
B*67 0.0 0.0 B*67 (100) yes
B*70 0.0 0.0 B*70 (100) yes
B*73 0.1 0.0 B*73 (100) yes
DRB1*01 7.7 11.9 DRB1*01 (100) no
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36779covariate to exclude possible hidden effects from population
stratification even though both populations were of Scandinavian
origin.
The correlation between the genotyped SNP (rs4959039) and
HLA-A allele groups was estimated with UNPHASED 3.0.13 as
for the haplotype analysis, but the complexity did not require
changing the tolerance for convergence in this case. To study the
effect of the SNP on MS susceptibility, logistic regression was
performed in R.
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